Immuneering Corp Appoints New CMO, Elects Director
Ticker: IMRX · Form: 8-K · Filed: May 23, 2024 · CIK: 1790340
| Field | Detail |
|---|---|
| Company | Immuneering Corp (IMRX) |
| Form Type | 8-K |
| Filed Date | May 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $3.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-election, personnel-change
Related Tickers: IMRX
TL;DR
Immuneering just brought in a new CMO and added a director to the board.
AI Summary
Immuneering Corp. announced on May 21, 2024, the appointment of Dr. Sarah E. Bloch as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its Board of Directors. The company also disclosed compensatory arrangements for its officers.
Why It Matters
These executive and board changes can signal shifts in the company's strategic direction and leadership, potentially impacting its drug development pipeline and future performance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Immuneering Corp (company) — Registrant
- Dr. Sarah E. Bloch (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Jones (person) — Elected to Board of Directors
- May 21, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Sarah E. Bloch has been appointed as the Chief Medical Officer.
Who has been elected to Immuneering Corp's Board of Directors?
Ms. Jennifer L. Jones has been elected to the Board of Directors.
What is the effective date of the events reported in this 8-K?
The earliest event reported is dated May 21, 2024.
What is Immuneering Corp's principal executive office address?
The principal executive offices are located at 245 Main St. Second Floor, Cambridge, MA 02142.
What is Immuneering Corp's telephone number?
The company's telephone number is (617) 500-8080.
Filing Stats: 833 words · 3 min read · ~3 pages · Grade level 13.6 · Accepted 2024-05-23 16:10:44
Key Financial Figures
- $0.001 — stered Class A common stock, par value $0.001 per share IMRX The Nasdaq Global Market
- $3.01 — n exercise price per share greater than $3.01 that were held by current employees and
Filing Documents
- imrx-20240521.htm (8-K) — 24KB
- 0001790340-24-000058.txt ( ) — 153KB
- imrx-20240521.xsd (EX-101.SCH) — 2KB
- imrx-20240521_lab.xml (EX-101.LAB) — 23KB
- imrx-20240521_pre.xml (EX-101.PRE) — 13KB
- imrx-20240521_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNEERING CORPORATION Date: May 23, 2024 By: /s/ Michael D. Bookman Name: Michael D. Bookman Title: Chief Legal Officer and Secretary